Diabetes mellitus type 1 natural history, complications, and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 76: | Line 76: | ||
* A study demonstrated that children with [[Diabetes mellitus type 1|type 1 diabetes]] mentioned barriers for physical activity (eg, fear of [[hypoglycemia]], loss of control of [[diabetes]] and low fitness). This study report significant improvement with parental support. <ref name="JabbourHenderson2016">{{cite journal|last1=Jabbour|first1=Georges|last2=Henderson|first2=Mélanie|last3=Mathieu|first3=Marie-Eve|title=Barriers to Active Lifestyles in Children with Type 1 Diabetes|journal=Canadian Journal of Diabetes|volume=40|issue=2|year=2016|pages=170–172|issn=14992671|doi=10.1016/j.jcjd.2015.12.001}}</ref> | * A study demonstrated that children with [[Diabetes mellitus type 1|type 1 diabetes]] mentioned barriers for physical activity (eg, fear of [[hypoglycemia]], loss of control of [[diabetes]] and low fitness). This study report significant improvement with parental support. <ref name="JabbourHenderson2016">{{cite journal|last1=Jabbour|first1=Georges|last2=Henderson|first2=Mélanie|last3=Mathieu|first3=Marie-Eve|title=Barriers to Active Lifestyles in Children with Type 1 Diabetes|journal=Canadian Journal of Diabetes|volume=40|issue=2|year=2016|pages=170–172|issn=14992671|doi=10.1016/j.jcjd.2015.12.001}}</ref> | ||
* Based on a [[systematic review]], [[Diabetes mellitus type 1|type 1 diabetic]] patients have worse [[Executive system|executive function]] performance, working memory and task switching, compared to the [[Scientific control|control group]].<ref name="BroadleyWhite2017">{{cite journal|last1=Broadley|first1=Melanie M.|last2=White|first2=Melanie J.|last3=Andrew|first3=Brooke|title=A Systematic Review and Meta-analysis of Executive Function Performance in Type 1 Diabetes Mellitus|journal=Psychosomatic Medicine|volume=79|issue=6|year=2017|pages=684–696|issn=0033-3174|doi=10.1097/PSY.0000000000000460}}</ref> | * Based on a [[systematic review]], [[Diabetes mellitus type 1|type 1 diabetic]] patients have worse [[Executive system|executive function]] performance, working memory and task switching, compared to the [[Scientific control|control group]].<ref name="BroadleyWhite2017">{{cite journal|last1=Broadley|first1=Melanie M.|last2=White|first2=Melanie J.|last3=Andrew|first3=Brooke|title=A Systematic Review and Meta-analysis of Executive Function Performance in Type 1 Diabetes Mellitus|journal=Psychosomatic Medicine|volume=79|issue=6|year=2017|pages=684–696|issn=0033-3174|doi=10.1097/PSY.0000000000000460}}</ref> | ||
* The followings are some related [[dermatology|dermatological]] consequences of [[Diabetes mellitus type 1|type 1 diabetes]]: | * The followings are some related [[dermatology|dermatological]] consequences of [[Diabetes mellitus type 1|type 1 diabetes]]:<ref name="pmid29465926">{{cite journal| author=Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K | display-authors=etal| title=Endotext | journal= | year= 2000 | volume= | issue= | pages= | pmid=29465926 | doi= | pmc= | url= }} </ref> | ||
** [[Scleroderma]]-like skin changes: Pathogenesis is not fully understood, nevertheless advanced glycosylation end products and [[sugar]] alcohols buildup in the upper [[dermis]] is believed to effect the strengthening of [[collagen]]. | ** [[Scleroderma]]-like skin changes: [[Pathogenesis]] is not fully understood, nevertheless advanced glycosylation end products and [[sugar]] [[alcohol|alcohols]] buildup in the upper [[dermis]] is believed to effect the strengthening of [[collagen]]. | ||
** Cheiroarthropathy (thickened skin and reduced joint mobility) | ** Cheiroarthropathy (thickened skin and reduced joint mobility) | ||
** Scleredema diabeticorum | ** Scleredema diabeticorum | ||
** [[Necrobiosis | ** [[Necrobiosis lipoidica]] | ||
[[File:Necrobiosis Lipoidica .png|alt=Necrobiosis Lipoidica |center|thumb|600x600px|Necrobiosis Lipoidica in type 1 diabetes, Case courtesy by Nandini Chatterjee<ref>{{Cite web|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987274/|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>]] | [[File:Necrobiosis Lipoidica .png|alt=Necrobiosis Lipoidica |center|thumb|600x600px|Necrobiosis Lipoidica in [[Diabetes mellitus type 1|type 1 diabetes]], Case courtesy by Nandini Chatterjee<ref>{{Cite web|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987274/|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>]] | ||
** Bullosis | ** Bullosis diabeticorum | ||
** | ** [[Xerosis]] | ||
** Eruptive [[xanthoma|xanthomas]]: Although [[xanthoma|xanthomas]] are routinely related to hypertriglyceridemia, [[Diabetes mellitus type 1|type 1 diabetic]] patients may develop eruptive [[xanthoma|xanthomas]] with normal levels of [[triglyceride]]. [[Prevelance]] of Eruptive [[xanthoma|xanthomas]] in [[Diabetes mellitus type 1|type 1 diabetes]] is approximately 1%. | |||
Revision as of 06:15, 30 August 2020
Diabetes mellitus type 1 Microchapters |
Differentiating Diabetes mellitus type 1 from other Diseases |
Diagnosis |
Treatment |
Cardiovascular Disease and Risk Management |
Case Studies |
Diabetes mellitus Main page |
Patient Information |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]
Overview
If left untreated, patients with [type 1 DM] may progress to develop complications of the hyperglycemia state, which commonly include diabetes ketoacidosis and hyperglycemia hyperosmolar state. Prognosis is generally good with compliance with medications.
Natural History
- The symptoms of type 1 diabetes usually develop in the first decade of life, and start with non-specific symptoms of classic new onset type 1 diabetes or acute symptoms with diabetic ketoacidosis. Without treatment, the patient will develop complications of type 1 diabetes.[1]
Complications
- Complications for type 1 diabetes include:[2][3][4][5]
Complications of Diabetes | |
---|---|
Acute Complications due to hyperglycemia | |
Microvascular complications | Eye disease
Neuropathy Sensory and motor (mono- and polyneuropathy) and Autonomic neuropathy Nephropathy (albuminuria and declining renal function) |
Macrovascular complications | Coronary heart disease |
Other | Gastrointestinal (gastroparesis, diarrhea)
Genitourinary (uropathy/sexual dysfunction) Cheiroarthropathy (thickened skin and reduced joint mobility) Fatty liver disease Low testosterone in men |
- In a control study patients with type 1 diabetes had significantly lower total body bone mineral density (BMD) z-score values. Lower levels of osteocalcin, C-terminal telopeptide, calcium, phosphorus, and magnesium have been found in patients with type 1 diabetes compared to control group.[6]
- A study demonstrated that children with type 1 diabetes mentioned barriers for physical activity (eg, fear of hypoglycemia, loss of control of diabetes and low fitness). This study report significant improvement with parental support. [7]
- Based on a systematic review, type 1 diabetic patients have worse executive function performance, working memory and task switching, compared to the control group.[8]
- The followings are some related dermatological consequences of type 1 diabetes:[9]
- Scleroderma-like skin changes: Pathogenesis is not fully understood, nevertheless advanced glycosylation end products and sugar alcohols buildup in the upper dermis is believed to effect the strengthening of collagen.
- Cheiroarthropathy (thickened skin and reduced joint mobility)
- Scleredema diabeticorum
- Necrobiosis lipoidica
- Bullosis diabeticorum
- Xerosis
- Eruptive xanthomas: Although xanthomas are routinely related to hypertriglyceridemia, type 1 diabetic patients may develop eruptive xanthomas with normal levels of triglyceride. Prevelance of Eruptive xanthomas in type 1 diabetes is approximately 1%.
Prognosis
- Diabetes is a lifelong disease and there is no cure. Tight control of blood glucose can prevent or delay diabetes complications. But these problems can occur, even in people with good diabetes control.[11]
References
- ↑ Achenbach P, Bonifacio E, Koczwara K, Ziegler AG (2005). "Natural history of type 1 diabetes". Diabetes. 54 Suppl 2: S25–31. PMID 16306336.
- ↑ "ADA".
- ↑ Type 1 Diabetes mellitus "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 27th,2016
- ↑ Type 1 Diabetes mellitus "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 27th,2016
- ↑ Teng, Zhi-Pan; Tian, Rui; Xing, Fen-Li; Tang, Hui; Xu, Jin-Jing; Zhang, Bing-Wen; Qi, Jian-Wei (2017). "An association of type 1 diabetes mellitus with auditory dysfunction: A systematic review and meta-analysis". The Laryngoscope. 127 (7): 1689–1697. doi:10.1002/lary.26346. ISSN 0023-852X.
- ↑ Leão, Andreia Araújo Porchat; Fritz, Camilla Kapp; Dias, Marcia Regina Messaggi Gomes; Carvalho, Julienne Angela Ramires; Mascarenhas, Luis Paulo Gomes; Cat, Mônica Nunes Lima; Radominski, Rosana; Nesi-França, Suzana (2020). "Bone mass and dietary intake in children and adolescents with type 1 diabetes mellitus". Journal of Diabetes and its Complications. 34 (6): 107573. doi:10.1016/j.jdiacomp.2020.107573. ISSN 1056-8727.
- ↑ Jabbour, Georges; Henderson, Mélanie; Mathieu, Marie-Eve (2016). "Barriers to Active Lifestyles in Children with Type 1 Diabetes". Canadian Journal of Diabetes. 40 (2): 170–172. doi:10.1016/j.jcjd.2015.12.001. ISSN 1499-2671.
- ↑ Broadley, Melanie M.; White, Melanie J.; Andrew, Brooke (2017). "A Systematic Review and Meta-analysis of Executive Function Performance in Type 1 Diabetes Mellitus". Psychosomatic Medicine. 79 (6): 684–696. doi:10.1097/PSY.0000000000000460. ISSN 0033-3174.
- ↑ Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K; et al. (2000). "Endotext". PMID 29465926.
- ↑ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987274/. Missing or empty
|title=
(help) - ↑ "Diabetes in control".